Serum uric acid: A forgotten prognostic marker in acute coronary syndromes?

European Heart Journal: Acute Cardiovascular Care

Volumn 2, Issue 1, 2013, Pages 44-52

  Timóteo, Ana t ^a   Lousinha, Ana ^a   Labandeiro, Jorge ^a   Miranda, Fernando ^a   Papoila, Ana l ^a   Oliveira, José A ^a   Ferreira, Maria l ^a   Ferreira, Rui c ^a  

^a HOSPITAL DE SANTA MARTA   (Portugal)

Author keywords

Acute coronary syndromes; prognosis; serum uric acid

Indexed keywords

EID: 84990348586     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872612474921     Document Type: Article

References (30)

1. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858–865.
2. Fessel WJ. High uric acid as an indicator of cardiovascular disease: independence from obesity. Am J Med 1980; 68: 401–404.
3. Fang J and Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992: National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404–2410.
4. Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951–1956.
5. Levya F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814–1822.
6. Cockcroft DW and Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
7. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 2003; 163: 2345–2353.
8. Pencina MJ, D' Agostino RB and Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statis Med 2011; 30: 11–21.
9. Nieto FJ, Iribarren C, Gross MD, et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131–139.
10. Hayden MR and Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab 2004; 1: 10.
11. Hare JM and Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003; 107: 1951–1953.
12. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991–1997.
13. Basar N, Sen N, Ozcan F, et al. Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. J Invest Med 2011; 59: 931–937.
14. Feig DI, Kang DH and Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811–1821.
15. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183–1890.
16. Culleton BF, Lansom MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.
17. Homayounfar S, Ansari M and Kashani KM. Evaluation of independent prognostic importance of hyperuricemia in hospital death after acute myocardial infarction. Saudi Med J 2007; 28: 759–761.
18. Lazzeri C, Valente S, Chiostri M, et al. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers. Int J Cardiol 2010; 21: 206–209.
19. Lazzeri C, Valente S, Chiostri, et al. Uric acid in the early risk stratification of ST-elevation myocardial infarction. Intern Emerg Med 2012; 7: 33–39.
20. Kojima S, Sakamoto T, Ishihara M, et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005; 96: 489–495.
21. Bae MH, Lee JH, Lee SH, et al. Serum uric acid as an independent and incremental prognostic marker in addition to N-terminal Pro-B-type natriuretic peptide in patients with acute myocardial infarction. Circ J 2011; 75: 1440–1447.
22. Car S and Trkulja V. Higher serum uric acid on admission is associated with higher short-term mortality and poorer long-term survival after myocardial infarction: retrospective prognostic study. Croat Med J 2009; 50: 559–566.
23. Akpek M, Kaya M, Uyarel H, et al. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. Atherosclerosis 2011; 219: 334–341.
24. Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hiperuricemia. Am J Cardiol 2005; 96: 1576–1578.
25. Ndrepepa G, Braun S, Haase HU, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol 2012; 109: 1260–1265.
26. Kaya M, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012; 109: 486–491.
27. Gotsman I, Keren A and Lotan C. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 2012; 18: 694–701.
28. Wei L, Fahey T, Struthers AD, et al. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 2009; 63: 1327–1333.
29. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105: 2619–2624.
30. Rentoukas E, Tsarouhas K, Tsitsimpikou C, et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary interventions. Int J Cardiol 2010; 145: 257–258.